Yonglan Huang

Ms. Yonglan Huang

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2016 in Hormone and Metabolic Research
Verified
Journal Article
Closed access
PDF file
MTM. Tan
M. Tan
YHYonglan Huang
Yonglan Huang
XJX. Jiang
X. Jiang
PLP. Li
P. Li
CTC. Tang
C. Tang
LLL. Liu
L. Liu
Thyroid dyshormonogenesis (DH) has recently been reported to be more frequently associated with mutations in the dual oxidase 2 (DUOX2) gene. The present study was aimed to investigate the prevalence, clinical, and molecular characteristics of congenital hypothyroidism (CH) caused by DUOX2 mutations in Guangzhou. A population-based cohort of 156 patients with CH was recruited based on neonatal screening among 433 578 newborns born in Guangzhou from 2011 to 2012. Genetic analysis of DUOX2 was performed in 96 patients with suspected thyroid dyshormonogenesis (SDH) by PCR-amplified direct sequencing. Apart from 2 cases without ultrasonographic data, 118 (76.6%) of the 156 patients were classified as SDH and 36 (23.4%) as thyroid dysgenesis (TD) according to thyroid ultrasound at diagnosis. Genetic analysis revealed 23 different variants in 60 unrelated individuals (60/96, 62.5%), including 13 novel variants that were absent from HGMD, dbSNP databases, and the 50 normal controls. The novel missense variants were predicted to be pathogenic by SIFT and PolyPhen-2. The p.K530X was the most common mutation. Ninety-three percent of mutant alleles occurred in exons 5, 6, 9, 14, 17, 20, 25, 27, and 28. There were no significant differences in phenotypes between biallelic and monoallelic variants cases or between with-DUOX2 and non-DUOX2 variants cases. Most patients with DUOX2 defects (78.2%) were transient CH. In conclusion, the prevalence of DUOX2 pathogenic variants was high (62.5%) in this cohort. Thirteen novel probably pathologic variants were reported. The p.K530X was the most common mutation in the Chinese population. There was no correlation between DUOX2 genotypes and clinical phenotypes.

25 February 2017 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
MJMinyan Jiang
Minyan Jiang
SLSha Liu
Sha Liu
HJHua Jiang
Hua Jiang
YLYunting Lin
Yunting Lin
YSYongxian Shao
Yongxian Shao
LLLi Liu
Li Liu

Verified
Journal Article
Open access
PDF file
CTChengfang Tang
Chengfang Tang
LLLixin Li
Lixin Li
TCTing Chen
Ting Chen
LYLi Yulin
Li Yulin
BZBo Zhu
Bo Zhu
YHYonglan Huang
Yonglan Huang
The aim of this study was to observe the outcomes of newborn screening (NBS) in a certain population by using next-generation sequencing (NGS) as a first-tier screening test combined with tandem mass spectrometry (MS/MS). We performed a multicenter study of 29,601 newborns from eight screening centers with NBS via NGS combined with MS/MS. A custom-designed panel targeting the coding region of the 142 genes of 128 inborn errors of metabolism (IEMs) was applied as a first-tier screening test, and expanded NBS using MS/MS was executed simultaneously. In total, 52 genes associated with the 38 IEMs screened by MS/MS were analyzed. The NBS performance of these two methods was analyzed and compared respectively. A total of 23 IEMs were diagnosed via NGS combined with MS/MS. The incidence of IEMs was approximately 1 in 1287. Within separate statistical analyses, the positive predictive value (PPV) for MS/MS was 5.29%, and the sensitivity was 91.3%. However, for genetic screening alone, the PPV for NGS was 70.83%, with 73.91% sensitivity. The three most common IEMs were methylmalonic academia (MMA), primary carnitine deficiency (PCD) and phenylketonuria (PKU). The five genes with the most common carrier frequencies were PAH (1:42), PRODH (1:51), MMACHC (1:52), SLC25A13 (1:55) and SLC22A5 (1:63). Our study showed that NBS combined with NGS and MS/MS improves the performance of screening methods, optimizes the process, and provides accurate diagnoses.

1 February 2018 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
YFYuyu Feng
Yuyu Feng
YHYonglan Huang
Yonglan Huang
CTChengfang Tang
Chengfang Tang
HHHao Hu
Hao Hu
XZXiaoyuan Zhao
Xiaoyuan Zhao
LLLi Liu
Li Liu

1 January 2021 in Clinical Biochemistry
Verified
Journal Article
Closed access
CTChengfang Tang
Chengfang Tang
XJXuefang Jia
Xuefang Jia
FTFang Tang
Fang Tang
SLSichi Liu
Sichi Liu
XJXiang Jiang
Xiang Jiang
YHYonglan Huang
Yonglan Huang

14 February 2021 in Experimental Biology and Medicine
Verified
Journal Article
Closed access
PDF file
SLSichi Liu
Sichi Liu
YFYuyu Feng
Yuyu Feng
YHYonglan Huang
Yonglan Huang
XJXiaoling Jiang
Xiaoling Jiang
CTChengfang Tang
Chengfang Tang
LLLi Liu
Li Liu
GM1 gangliosidosis is a rare lysosomal storage disease caused by a deficiency of β-galactosidase due to mutations in the GLB1 gene. We established a C57BL/6 mouse model with Glb1G455R mutation using CRISPR/Cas9 genome editing. The β-galactosidase enzyme activity of Glb1G455R mice measured by fluorometric assay was negligible throughout the whole body. Mutant mice displayed no marked phenotype at eight weeks. After 16 weeks, GM1 ganglioside accumulation in the brain of mutant mice was observed by immunohistochemical staining. Meanwhile, a declining performance in behavioral tests was observed among mutant mice from 16 to 32 weeks. As the disease progressed, the neurological symptoms of mutant mice worsened, and they then succumbed to the disease by 47 weeks of age. We also observed microglia activation and proliferation in the cerebral cortex of mutant mice at 16 and 32 weeks. In these activated microglia, the level of autophagy regulator LC3 was up-regulated but the mRNA level of LC3 was normal. In conclusion, we developed a novel murine model that mimicked the chronic phenotype of human GM1. This Glb1G455R murine model is a practical in vivo model for studying the pathogenesis of GM1 gangliosidosis and exploring potential therapies.